论文部分内容阅读
目的了解肿瘤标记物CA125、CEA、CA19-9联合检测提高卵巢癌诊断的敏感性。方法对2005年3月-2008年6月收治的58例确诊卵巢癌患者、50例正常人血清进行CA125、CEA、CA19-93项肿瘤标记物的电化学发光免疫检测。结果 CA125、CEA、CA19-9单项检测的敏感度分别为79.3%、9.4%和25.9%,3项联合检测并联试验可提高试验的敏感度至86.2%,漏诊率降至13.8%。结论肿瘤标记物CA125、CEA、CA19-9联合检测可以提高恶性卵巢癌诊断的灵敏度和降低漏诊率,为卵巢肿瘤的早期诊断和治疗提供更可靠的实验依据。
Objective To investigate the combined detection of tumor markers CA125, CEA and CA19-9 in the diagnosis of ovarian cancer. Methods The serum levels of CA125, CEA and CA19-93 in 58 patients diagnosed as ovarian cancer and 50 normal persons admitted from March 2005 to June 2008 were detected by electrochemiluminescence immunoassay. Results The sensitivities of single detection of CA125, CEA and CA19-9 were 79.3%, 9.4% and 25.9% respectively. The three combined tests could increase the sensitivity of the test to 86.2% and the missed diagnosis rate to 13.8%. Conclusion Combined detection of tumor markers CA125, CEA and CA19-9 can improve the sensitivity and reduce the rate of misdiagnosis of ovarian cancer, and provide a more reliable experimental basis for the early diagnosis and treatment of ovarian tumors.